1.Survival and Clinical Behavior of Hypertrophic Cardiomyopathy in a Latin American Cohort in Contrast to Cohorts from the Developed World.
Nilda ESPINOLA-ZAVALETA ; Antonio VEGA ; Diego Martinez BASTO ; Ana Cecilia ALCANTAR-FERNANDEZ ; Veronica GUARNER LANS ; Maria Elena SOTO
Journal of Cardiovascular Ultrasound 2015;23(1):20-26
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is the most common hereditary heart disease with diverse phenotipyc, genetic expession and clinical presentations. The evolution of patients with HCM in Latin America has not been properly described being the frequency, the long-term prognosis as well as the predominant phenotypic expression still unknown. The aim of this study was to determine the survival rate of HCM patients having different phenotypes in a Mexican cohort of patients. METHODS: Clinical and echocardiographic data obtained from 77 Mexican patients with recently diagnosed HCM were analyzed. The follow-up was of 12.5 years. RESULTS: 96.1% of patients were in functional class I/II according to the New York Heart Association, 2.6% in class III and 1.3% in class IV. Only 3.9% of them went to surgery for myectomy. During the follow-up, 17 patients (22%) died: 4/9 (44%) had apical HCM, 5/20 (25%) had obstructive septal asymmetric HCM, 6/35 (17%) had nonobstructive septal asymmetric HCM and 2/3 (15%) had concentric HCM. The survival rate was worse for patients with apical HCM, followed by those with obstructive and nonobstructive septal asymmetric HCM and patients showing concentric HCM had the best survival rates. There is significant difference in survival rates which declined in 65% in a 9 years-period. Log rank test showed significant differences (p < 0.002). CONCLUSION: The survival rate of patients with HCM was worse in those with apical variety. The majority of patients received medical treatment. The indication for myectomy was below that observed in other international centers.
Cardiomyopathy, Hypertrophic*
;
Cohort Studies*
;
Echocardiography
;
Follow-Up Studies
;
Heart
;
Heart Diseases
;
Humans
;
Latin America
;
Phenotype
;
Prognosis
;
Survival Rate
2.Mediterranean Diet and Physical Activity Protect from Silent Brain Infarcts in a Cohort of Patients with Atrial Fibrillation
Irene ESCUDERO-MARTÍNEZ ; Fernando MANCHA ; Angela VEGA-SALVATIERRA ; María Irene AYUSO ; Rafael F OCETE ; Pilar ALGABA ; Antonio LÓPEZ-RUEDA ; Pilar PIÑERO ; Elena FAJARDO ; José Román FERNÁNDEZ-ENGO ; Eva María MARTÍN-SÁNCHEZ ; Alejandro GALVAO-CARMONA ; Elena ZAPATA-ARRIAZA ; Lucía LEBRATO ; Blanca PARDO-GALIANA ; Juan Antonio CABEZAS ; Alejandro GONZÁLEZ ; Francisco MONICHE ; Joan MONTANER
Journal of Stroke 2019;21(3):353-355
No abstract available.
Atrial Fibrillation
;
Brain
;
Cohort Studies
;
Diet, Mediterranean
;
Humans
;
Motor Activity
3.Fibroblast Growth Factor-23 is associated with High-density lipoprotein in Systemic sclerosis Female patients
Antonio Alvarez-Cienfuegos ; Lucia Cantero-Nieto ; Jose Alberto Garcí ; a-Gomez ; Jose Luis Callejas-Rubio ; Javier Martin ; Norberto Ortego-Centeno
Philippine Journal of Internal Medicine 2020;59(1):9-13
INTRODUCTION: Fibroblast growth factor-23 (FGF23) is a circulating regulator of phosphate and vitamin D metabolism and has been implicated as a putative pathogenic factor in cardiovascular disease. The objectives of this study were: to compare serum FGF23 levels between systemic sclerosis (SSc) patients and healthy controls and to investigate possible associations between FGF23 and serum lipid profile in SSc patients.
METHODS: This cross-sectional study was performed in San Cecilio Hospital, Granada (Spain) from November 2017 to May 2019. We enrolled 62 consecutive female patients affected by SSc and 62 healthy women who served as controls. Cardiovascular risk factors and related biochemical parameters were collected. Serum FGF23 was analyzed using enzyme- linked immunosorbent assay (ELISA). Linear regression was used to examine the cross-sectional associations of serum FGF23 concentrations with high density lipoprotein-cholesterol (HDL-c).
RESULTS: There was no significant differences in FGF23 levels between the patients and controls (78.2 ± 60.5 vs. 80.3 ± 56.3 pg/mL, p= 0.662), but we found a statistically significant inverse relationship between FGF23 and HDL-c measurements (r= -0.27; p= 0.03) in women with SSc. In addition, in the linear regression model, higher FGF23 concentrations were associated with lower HDL-c [β = -1.45 95% CI (-2.81, -0.08); p < 0.05].
CONCLUSIONS: We report an association between circulating FGF23 and HDL-c in SSc female patients, representing a novel pathway linking high FGF23 to an increased cardiovascular risk.
Lipoproteins, HDL
;
fibroblast growth factor 23
;
Scleroderma, Systemic
;
Fibroblast Growth Factors